When does Emergent BioSolutions’ Biothrax-related patent expire?
The provided information does not specify any Biothrax (anthrax vaccine) patent expiry dates tied to Emergent BioSolutions. Without the exact patent numbers, jurisdictions (US, EP, etc.), or the specific product/spit-out (for example, “Biothrax” formulation, manufacturing process, or method of use), the expiry date can’t be determined reliably.
Which patents matter for Biothrax exclusivity (and how could expiry differ)?
Even when a drug’s core biologic approval is old, different IP events can control market exclusivity:
- Patent protection can end at different times depending on whether it is a composition, formulation, manufacturing/process, or method-of-use claim.
- Regulatory exclusivity (distinct from patents) can extend or restrict competition even after some patents expire.
- If patents are licensed, challenged, or amended through litigation, the effective “can launch” timeline can shift.
To answer this precisely, you’d need at least one of the following: a patent publication number, a list of relevant claims, or the country/region for the exclusivity question.
Are competitors able to sell a generic/biosimilar Biothrax right after the last patent ends?
Biothrax is a biologic product, so the competitive picture depends on more than patent expiry:
- Biosimilar pathways are not always direct analogs to “generic” drug entry, and eligibility depends on the regulatory framework and what is being compared.
- Even if patents expire, manufacturing, regulatory approval, and any remaining blocking patents or exclusivity terms can delay entry.
A correct timeline requires mapping the specific blocking patents and any ongoing litigation or exclusivity.
What I need to give you an exact expiry date
Share any one of the following and I can pinpoint the likely expiry window:
- The patent number(s) or publication ID(s) you mean (USPTO publication, EP publication, etc.)
- The jurisdiction (US only, or also EU/UK)
- Whether you mean product exclusivity (Biothrax as marketed) or a specific aspect (process, formulation, or indication)
Sources
None provided.